Publications by authors named "Iwona Golda-Gocka"
Article Synopsis
- Immunotherapy has transformed the treatment of non-small cell lung cancer (NSCLC), but predicting which patients will benefit long-term is still challenging.
- A study analyzed serum levels of soluble CD8 antigen (sCD8) in 42 NSCLC patients undergoing atezolizumab therapy, finding that lower levels of sCD8 after two treatment cycles correlated with better progression-free and overall survival outcomes.
- Elevated sCD8 levels may indicate an immunosuppressive effect, hindering the activation of cytotoxic T-cells, which are crucial for effective cancer treatment.
Prognosis of advanced non-small cell lung carcinoma (NSCLC) is poor. Even though it can improve with anti-PD-1/PD-L1 agents, most patients do not respond to treatment. We hypothesized that the serum soluble form of the unit α of the interleukin-2 receptor (sCD25) could be used as a biomarker of successful immunotherapy in NSCLC.
View Article and Find Full Text PDF. To evaluate the involvement of glutamate metabolism in peripheral blood mononuclear cells (PBMC) in the development of neurological complications in lung cancer and during chemotherapy. .
View Article and Find Full Text PDFLung cancer is the leading cause of cancer-related death worldwide. Although treatment methods such as surgery, radiotherapy and/or chemotherapy have improved, prognosis remains unsatisfactory, and developing new therapeutic strategies is still an urgent matter. Immunotherapy is a novel therapeutic approach wherein activated immune cells can specifically kill tumour cells.
View Article and Find Full Text PDF